Transcat, Inc. (NASDAQ:TRNS) Stock Now Rated “Hold” by Wall Street Brokerages

Transcat, Inc. (NASDAQ:TRNS) has been assigned a consensus recommendation of “Hold” from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $108.33.

A number of analysts recently weighed in on TRNS shares. Weiss Ratings restated a “sell (d+)” rating on shares of Transcat in a research note on Tuesday, August 25th. Northland Securities upgraded shares of Transcat from a “market perform” rating to an “outperform” rating and set a $95.00 price target for the company in a research note on Wednesday, October 21st. Oppenheimer upgraded shares of Transcat from a “market perform” rating to an “outperform” rating and set a $115.00 price target for the company in a report on Wednesday. Finally, CJS Securities assumed coverage on shares of Transcat in a research report on Tuesday, October 27th. They issued an “outperform” rating and a $115.00 price objective on the stock.

Transcat Trading Up 1.8%

NASDAQ:TRNS opened at $89.52 on Wednesday. The firm has a market cap of $840.59 million, a PE ratio of 241.95 and a beta of 0.61. The stock has a fifty day moving average price of $86.10 and a 200 day moving average price of $81.83. Transcat has a 12-month low of $50.23 and a 12-month high of $100.00. The company has a current ratio of 2.49, a quick ratio of 2.11 and a debt-to-equity ratio of 0.36.

Transcat (NASDAQ:TRNS) last issued its quarterly earnings results on Tuesday, November 3rd. The scientific and technical instruments company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.19. The company had revenue of $97.09 million for the quarter, compared to the consensus estimate of $92.46 million. Transcat had a return on equity of 5.56% and a net margin of 0.99%. Sell-side analysts anticipate that Transcat will post 1.79 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Transcat news, Director Craig D. Cairns purchased 1,050 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were bought at an average cost of $93.97 per share, for a total transaction of $98,668.50. Following the completion of the purchase, the director directly owned 1,480 shares in the company, valued at approximately $139,075.60. This represents a 244.19% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Christopher Gillette sold 504 shares of Transcat stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $94.23, for a total value of $47,491.92. Following the sale, the director directly owned 200 shares of the company’s stock, valued at $18,846. This trade represents a 71.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 1.80% of the company’s stock.

Institutional Investors Weigh In On Transcat

Several hedge funds and other institutional investors have recently made changes to their positions in TRNS. Integrated Wealth Concepts LLC purchased a new stake in shares of Transcat in the 2nd quarter valued at about $32,000. Persistent Asset Partners Ltd purchased a new stake in Transcat in the second quarter valued at approximately $52,000. GAMMA Investing LLC boosted its holdings in shares of Transcat by 133.6% in the third quarter. GAMMA Investing LLC now owns 1,030 shares of the scientific and technical instruments company’s stock valued at $91,000 after acquiring an additional 589 shares during the period. Squarepoint Ops LLC boosted its holdings in shares of Transcat by 9.0% in the second quarter. Squarepoint Ops LLC now owns 8,794 shares of the scientific and technical instruments company’s stock valued at $816,000 after acquiring an additional 728 shares during the period. Finally, Corient Private Wealth LP grew its position in shares of Transcat by 9.1% during the second quarter. Corient Private Wealth LP now owns 9,509 shares of the scientific and technical instruments company’s stock worth $882,000 after acquiring an additional 791 shares during the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

Key Stories Impacting Transcat

Here are the key news stories impacting Transcat this week:

• Positive Sentiment: Transcat earned $0.64 per share, up from $0.44 a year earlier and above consensus estimates of roughly $0.42–$0.45. Revenue was $97.09 million, topping the $92.46 million estimate. Zacks earnings report
• Positive Sentiment: The company raised its fiscal 2027 outlook for service organic growth to the low double digits and is targeting at least 100 basis points of service gross-margin expansion in the second half. That outlook points to continued demand and improving service profitability. Outlook update
• Positive Sentiment: Management characterized the quarter as strong, citing double-digit organic service revenue growth and significant service gross-margin expansion. Transcat fiscal second-quarter results

About Transcat

Transcat, Inc (NASDAQ: TRNS) provides calibration, compliance, and measurement services for organizations that rely on accurate test and measurement equipment. The company supports customers in regulated industries, including life sciences, aerospace and defense, energy, manufacturing, and other industrial markets.

Its service offerings include laboratory and onsite calibration, repair, validation, and asset-management services. Transcat calibrates a broad range of equipment used to measure temperature, pressure, electrical and electronic properties, radio frequency signals, dimensional characteristics, and other technical parameters.